StockUS listing USDAWNNASDAQHealthcareEarnings Deterioration

Day One Biopharmaceuticals Inc(DAWN) Stock Analysis | Healthcare

USD --+0.00%
Reward53Moderate
Risk34Moderate
75%Data
Thin -114% profit margin · Revenue down 58% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.23Bn
Reward Ratingⓘ53 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ34 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DAWN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Day One Biopharmaceuticals Inc?

, a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

AI Brief Pro

The brief on Day One Biopharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Day One Biopharmaceuticals Inc?

, a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.23B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta-1.265
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
0
9-12months
536,461 shares
$423k
0